Dashboard
Manage Tickers

MBRXMoleculin Biotech, Inc.

Nasdaq moleculin.com


$ 4.67 $ 0.32 (7.47 %)    

Friday, 26-Apr-2024 10:48:50 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 431.01 $ 6.55 (1.54 %)
DIA $ 382.27 $ 1.39 (0.36 %)
SPY $ 508.26 $ 4.77 (0.95 %)
TLT $ 88.26 $ 0.46 (0.52 %)
GLD $ 216.60 $ 0.70 (0.32 %)
$ 4.63
$ 4.67
$ 0.00 x 0
$ 0.00 x 0
$ 4.67 - $ 4.67
$ 4.28 - $ 15.75
24,042
na
687,560
$ 1.37
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 03-22-2024 12-31-2023 10-K
2 11-13-2023 09-30-2023 10-Q
3 08-10-2023 06-30-2023 10-Q
4 05-10-2023 03-31-2023 10-Q
5 03-22-2023 12-31-2022 10-K
6 11-10-2022 09-30-2022 10-Q
7 08-12-2022 06-30-2022 10-Q
8 05-11-2022 03-31-2022 10-Q
9 03-24-2022 12-31-2021 10-K
10 11-10-2021 09-30-2021 10-Q
11 08-11-2021 06-30-2021 10-Q
12 05-12-2021 03-31-2021 10-Q
13 03-24-2021 12-31-2020 10-K
14 11-12-2020 09-30-2020 10-Q
15 08-12-2020 06-30-2020 10-Q
16 05-11-2020 03-31-2020 10-Q
17 03-19-2020 12-31-2019 10-K
18 11-12-2019 09-30-2019 10-Q
19 08-16-2019 06-30-2019 10-Q
20 05-13-2019 03-31-2019 10-Q
21 02-21-2019 12-31-2018 10-K
22 11-13-2018 09-30-2018 10-Q
23 08-10-2018 06-30-2018 10-Q
24 05-14-2018 03-31-2018 10-Q
25 03-28-2018 12-31-2017 10-K
26 11-13-2017 09-30-2017 10-Q
27 08-11-2017 06-30-2017 10-Q
28 05-12-2017 03-31-2017 10-Q
29 04-03-2017 12-31-2016 10-K
30 11-21-2016 09-30-2016 10-Q
31 08-15-2016 06-30-2016 10-Q
32 06-16-2016 03-31-2016 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

12-health-care-stocks-moving-in-fridays-pre-market-session
12 Health Care Stocks Moving In Friday's P...
04/26/2024 12:06:32

european-medicines-agency-grants-orphan-drug-designation-for-moleculins-treatment-of-acute-myeloid-leukemia
European Medicines Agency Grants Orphan Dr...
04/18/2024 12:36:14

roth-mkm-maintains-buy-on-moleculin-biotech-maintains-40-price-target
Roth MKM Maintains Buy on Moleculin Biotec...
04/12/2024 16:24:03

Roth MKM analyst Jonathan Aschoff maintains Moleculin Biotech (NASDAQ:MBRX) with a Buy and maintains $40 price target.

moleculin-presents-data-for-anthracycline
Moleculin Presents Data For Anthracycline
04/10/2024 12:34:09

12-health-care-stocks-moving-in-mondays-after-market-session
12 Health Care Stocks Moving In Monday's A...
04/08/2024 20:31:20

moleculin-received-us-patent-issue-notification-for-annamycin-targeting-unmet-need-in-aml
Moleculin Received U.S. Patent Issue Notif...
03/27/2024 13:06:48

maxim-group-maintains-buy-on-moleculin-biotech-lowers-price-target-to-20
Maxim Group Maintains Buy on Moleculin Bio...
03/26/2024 13:24:15

Maxim Group analyst Jason McCarthy maintains Moleculin Biotech (NASDAQ:MBRX) with a Buy and lowers the price target from $45...

moleculin-biotech-provided-a-preliminary-update-on-recent-clinical-activity-and-expected-near-term-milestones-for-its-lead-program-mb-106-for-the-treatment-of-acute-myeloid-leukemia
Moleculin Biotech Provided A Preliminary U...
03/25/2024 11:36:34

Annamycin in combination with Cytarabine (AnnAraC) achieves CRc rate of 60% (50% CR) in 2nd line AML subjects AnnAraC has po...

moleculin-biotech-fy23-eps-1507-vs-1522-yoy-as-of-december-31-2023-the-company-had-cash-and-cash-equivalents-of-236m
Moleculin Biotech FY23 EPS $(15.07) Vs $(1...
03/22/2024 20:10:32

Summary of Financial Results for the Full Year 2023Research and development (R&D) expenses were $19.5 million and $19.0 mil...

trading-halt-halt-status-updated-at-85500-am-et-quotation-resumption-news-and-resumption-times
Trading Halt: Halt status updated at 8:55:...
03/22/2024 12:55:04

earnings-scheduled-for-march-22-2024
Earnings Scheduled For March 22, 2024
03/22/2024 09:40:22

Companies Reporting Before The Bell • Agile Therapeutics (NASDAQ:AGRX) is likely to report quarterly loss at $0.54 per share o...

trading-halt-halted-at-75000-pm-et---trading-halt-halt-news-pending
Trading Halt: Halted at 7:50:00 p.m. ET - ...
03/21/2024 23:50:04

a-preview-of-moleculin-biotechs-earnings
A Preview Of Moleculin Biotech's Earnings
03/21/2024 14:00:50

micron-signet-jewelers-and-3-stocks-to-watch-heading-into-wednesday
Micron, Signet Jewelers And 3 Stocks To Wa...
03/20/2024 06:44:55

With U.S. stock futures trading lower this morning on Wednesday, some of the stocks that may grab investor focus today are as f...

12-health-care-stocks-moving-in-tuesdays-after-market-session
12 Health Care Stocks Moving In Tuesday's ...
03/19/2024 21:34:06

moleculin-announces-1-for-15-reverse-stock-split
Moleculin Announces 1-For-15 Reverse Stock...
03/19/2024 20:32:52

12-health-care-stocks-moving-in-mondays-pre-market-session
12 Health Care Stocks Moving In Monday's P...
03/18/2024 13:05:55

12-health-care-stocks-moving-in-mondays-after-market-session
12 Health Care Stocks Moving In Monday's A...
03/04/2024 21:32:25

moleculin-announces-year-end-annamycin-clinical-trials-preliminary-data-and-2024-expectations-for-multiple-data-readouts-and-transition-to-pivotal-phase-2b3
Moleculin Announces Year-End Annamycin Cli...
01/24/2024 13:58:22

– MB-106 AML Phase 1B/2 trial (MB-106) preliminary data readout: Reached 67% recruitment– MB-106 preliminary results: Intent to...

12-health-care-stocks-moving-in-tuesdays-after-market-session
12 Health Care Stocks Moving In Tuesday's ...
01/23/2024 21:31:04

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION